"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
- Clinician Information:
Metrodin Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Metrodin (urofollitropin for injection) is a gonadotropin used to stimulate follicular development and the induction of ovulation in patients with polycystic ovary syndrome, and infertility, who have failed to respond or conceive following adequate clomiphene citrate therapy. Metrodin and hCG may also be used to stimulate the development of multiple follicles in ovulatory patients undergoing Assisted Reproductive Technologies (ART) such as in vitro fertilization. The brand name of this medication is discontinued, but generic versions may be available. Common side effects include breast tenderness, nausea, vomiting, and diarrhea.
The dose of Metrodin to stimulate development of the follicle is individualized for each patient. Metrodin may interact with other drugs. Tell your doctor all medications and supplements you use. Metrodin is not recommended for use during pregnancy. It may harm a fetus. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Metrodin (urofollitropin for injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Metrodin FDA Prescribing Information: Side Effects
The following adverse reactions reported during Metrodin® (urofollitropin for injection) therapy are listed in decreasing order of potential severity:
3. Adnexal torsion (as a complication of ovarian enlargement),
4. Mild to moderate ovarian enlargement,
5. Abdominal pain,
6. Sensitivity to Metrodin® (urofollitropin for injection) ,
(Febrile reactions which may be accompanied by chills, musculoskeletal aches, joint pains, malaise, headache, and fatigue have occurred after the administration of Metrodin® (urofollitropin for injection) . It is not clear whether or not these were pyrogenic responses or possible allergic reactions.)
7. Ovarian cysts,
10. Breast tenderness,
13. Hemoperitoneum has been reported during menotropins therapy and, therefore, may also occur during Metrodin® (urofollitropin for injection) therapy.
14. There have been infrequent reports of ovarian neoplasms, both benign and malignant, in women who have undergone multiple drug regimens for ovulation induction; however, a causal relationship has not been established.
The following medical events have been reported subsequent to pregnancies resulting from Metrodin® (urofollitropin for injection) therapy:
2. Congenital abnormalities
(Three incidents of chromosomal abnormalities and four birth defects have been reported following Metrodin® (urofollitropin for injection) -hCG or Metrodin® (urofollitropin for injection) , Pergonal® (menotropins for injection, USP) hCG therapy in clinical trials for stimulation prior to in vitro fertilization. The aborted pregnancies included one Trisomy 13, one Trisomy 18, and one fetus with multiple congenital anomalies (hydrocephaly, omphalocele, and meningocele). One meningocele, one external ear defect, one dislocated hip and ankle, and one dilated cardiomyopathy in presence of maternal Systemic Lupus Erythematosis were reported. None of these events was thought to be drug-related. The incidence does not exceed that found in the general population.)
Drug Abuse and Dependence
There have been no reports of abuse or dependence with Metrodin® (urofollitropin for injection) .
Read the entire FDA prescribing information for Metrodin (Urofollitropin for Injection) »
Additional Metrodin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.